Ligand Pharmaceuticals Incorporated
LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxā¦ read more
Healthcare
Biotechnology
33 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$220.95
Price-0.47%
-$1.05
1Y
Price
Market Cap
$4.428b
Mid
Price/Earnings 3y Avg5y Avg
28.8x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+33.6%
EBITDA Margin-25.8%
Net Profit Margin+93.7%
Free Cash Flow Margin+33.6%
EBITDA Margin-25.8%
Net Profit Margin+93.7%
Free Cash Flow MarginRevenue
$274.476m
+2.4%
1y CAGR+30.0%
3y CAGR+14.2%
5y CAGREarnings
$153.559m
+23.4%
1y CAGR+1034.1%
3y CAGR+839.7%
5y CAGREPS
$7.37
+20.2%
1y CAGR+933.0%
3y CAGR+761.9%
5y CAGRBook Value
$997.322m
$1.532b
Assets$534.783m
Liabilities$451.977m
DebtDebt to Assets
29.5%
1.8x
Debt to EBITDAFree Cash Flow
$122.956m
+151.4%
1y CAGR+675.5%
3y CAGR+480.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company